[go: up one dir, main page]

Buchholz et al., 2022 - Google Patents

The TAU isoform 1N4R restores vulnerability of MAPT knockout human iPSC-derived neurons to amyloid beta-induced neuronal dysfunction

Buchholz et al., 2022

View PDF
Document ID
3332662736158563741
Author
Buchholz S
Bell-Simons M
Al Kabbani M
Kluge L
Cagkmak C
Klimek J
Zempel H
Publication year

External Links

Snippet

The microtubule-associated protein TAU is a key driver of the neurodegeneration observed in Alzheimer's disease (AD). Normally, TAU stabilizes neuronal microtubules (MT) and promotes essential MT-associated functions. Alternative splicing of the TAU-encoding MAPT …
Continue reading at www.researchgate.net (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology

Similar Documents

Publication Publication Date Title
Liang et al. Stabilization of heterochromatin by CLOCK promotes stem cell rejuvenation and cartilage regeneration
Guo et al. HDAC6 inhibition reverses axonal transport defects in motor neurons derived from FUS-ALS patients
Zhong et al. Upstream open reading frame with NOTCH2NLC GGC expansion generates polyglycine aggregates and disrupts nucleocytoplasmic transport: implications for polyglycine diseases
García‐León et al. Generation of a human induced pluripotent stem cell–based model for tauopathies combining three microtubule‐associated protein TAU mutations which displays several phenotypes linked to neurodegeneration
Irobi et al. Mutant HSPB8 causes motor neuron-specific neurite degeneration
Oh et al. S-Nitrosylation of p62 inhibits autophagic flux to promote α-synuclein secretion and spread in Parkinson's disease and Lewy body dementia
JP2016513475A (en) Cellular discovery platform for neurodegenerative diseases
Kim et al. RNA methyltransferase NSun2 deficiency promotes neurodegeneration through epitranscriptomic regulation of tau phosphorylation
EP2781601B1 (en) Method for producing insoluble aggregate of neurodegenerative-disease-related protein
Kuliyev et al. Overlapping role of SCYL1 and SCYL3 in maintaining motor neuron viability
Buchholz et al. The TAU isoform 1N4R restores vulnerability of MAPT knockout human iPSC-derived neurons to amyloid beta-induced neuronal dysfunction
Buchholz et al. The tau isoform 1N4R confers vulnerability of MAPT knockout human iPSC‐derived neurons to amyloid beta and phosphorylated tau‐induced neuronal dysfunction
Vieira de Sá et al. ATAXIN-2 intermediate-length polyglutamine expansions elicit ALS-associated metabolic and immune phenotypes
Blazejewski et al. Rpsa signaling regulates cortical neuronal morphogenesis via its ligand, PEDF, and plasma membrane interaction partner, Itga6
Lam et al. Rapid iPSC inclusionopathy models shed light on formation, consequence and molecular subtype of α-synuclein inclusions
Chong et al. Presenilin-1 F105C mutation leads to tau accumulation in human neurons via the Akt/mTORC1 signaling pathway
Kong et al. Fine-tuning of mTOR signaling by the UBE4B-KLHL22 E3 ubiquitin ligase cascade in brain development
Merour et al. Transient regulation of focal adhesion via Tensin3 is required for nascent oligodendrocyte differentiation
Yokoi et al. The SYNGAP1 3′ UTR variant in ALS patients causes aberrant SYNGAP1 splicing and dendritic spine loss by recruiting HNRNPK
Parrotta et al. Modeling sporadic progressive supranuclear palsy in 3D midbrain organoids: recapitulating disease features for in vitro diagnosis and drug discovery
Zhao et al. Alzheimer’s disease protective allele of Clusterin modulates neuronal excitability through lipid-droplet-mediated neuron-glia communication
WO2019143978A1 (en) Gene editing-based method of attenuating the beta-amyloid pathway
JP2019524158A (en) Cortical neuron model of Alzheimer's disease based on BMI1 deficiency and use thereof
Pereira et al. Nuclear aging in polyglutamine-induced neurodegeneration
EP4549585A1 (en) Kit for diagnosing alzheimer's disease and pharmaceutical composition for treating alzheimer's disease